Compare PROF & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROF | RCS |
|---|---|---|
| Founded | N/A | 1994 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.8M | 239.6M |
| IPO Year | 2017 | 1994 |
| Metric | PROF | RCS |
|---|---|---|
| Price | $7.44 | $4.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $11.14 | N/A |
| AVG Volume (30 Days) | ★ 184.5K | 129.9K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.12% |
| EPS Growth | ★ 25.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,098,000.00 | N/A |
| Revenue This Year | $61.76 | N/A |
| Revenue Next Year | $70.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 50.73 | N/A |
| 52 Week Low | $4.91 | $4.84 |
| 52 Week High | $8.95 | $7.04 |
| Indicator | PROF | RCS |
|---|---|---|
| Relative Strength Index (RSI) | 62.40 | 45.22 |
| Support Level | $6.38 | $4.87 |
| Resistance Level | $7.92 | $5.67 |
| Average True Range (ATR) | 0.50 | 0.09 |
| MACD | 0.13 | 0.00 |
| Stochastic Oscillator | 75.61 | 34.62 |
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with their objective.